Dose-Dense Chemotherapy for Breast Cancer
Clifford A. Hudis, MD, chief, Breast Medicine Service, Memorial Sloan Kettering Cancer Center, discusses dose-dense chemotherapy for the treatment of patients with breast cancer.
Clinical Pearls
Clifford A. Hudis, MD, chief, Breast Medicine Service, Memorial Sloan Kettering Cancer Center, discusses dose-dense chemotherapy for the treatment of patients with breast cancer.
- Early mathematical models suggested scheduling might be a viable alternative strategy to escalating the dose of conventional cytotoxic chemotherapies.
- The big breakthrough in this area was the development of growth factors in the 1980s and 1990s.
- This strategy represents a useful backbone for targeted therapies.
Leon-Ferre Explores Targeting of PIK3CA Alterations in ER+ Breast Cancer
July 24th 2024During a live Community Case Forum event in partnership with the Minnesota Society of Clinical Oncology, Roberto A. Leon-Ferre, MD, discussed drugs targeting PIK3CA alterations in patients with ER+ metastatic breast cancer.
Read More
Breast Cancer Leans into the Decade of Antibody-Drug Conjugates, Experts Discuss
September 25th 2020In season 1, episode 3 of Targeted Talks, the importance of precision medicine in breast cancer, and how that vitally differs in community oncology compared with academic settings, is the topic of discussion.
Listen
Dato-DXd Shows Promise as a More Tolerable ADC in HER2-Negative mBC
July 22nd 2024During a Case-Based Roundtable® event, Igor Makhlin, MD, discussed with participants their impressions of datopotamab deruxtecan as therapy for patients with HR-positive, HER2-negative breast cancer, and the sequential use of multiple antibody-drug conjugates.
Read More
